WEBULL

Penny Stocks To Watch In July 2026

Simply Wall St · 1d ago

In the last week, the market has been flat, though it is up 21% over the past year with earnings expected to grow by 18% per annum in the coming years. Investing in penny stocks—often associated with smaller or newer companies—can still open doors to growth opportunities when these stocks are supported by strong financial health. We'll explore several penny stocks that stand out for their financial strength and potential for long-term success.

Below we spotlight a couple of our favorites from our exclusive screener.

Freightos (CRGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Freightos Limited operates a vendor-neutral booking and payment platform for international freight across various regions, including Spain, Europe, Hong Kong, and the United States, with a market cap of $64.60 million.

Operations: Freightos Limited has not reported any specific revenue segments.

Market Cap: $64.6M

Freightos Limited, with a market cap of US$64.60 million, is navigating its position in the penny stock landscape through strategic partnerships and financial resilience. The recent integration with Korean Air Co. Ltd. enhances Freightos' platform capabilities, offering real-time booking and pricing to freight forwarders across major global trade lanes. Despite being unprofitable, Freightos has shown revenue growth from US$6.95 million to US$7.16 million year-over-year for Q1 2026 and maintains a cash runway of over a year without debt burdening its balance sheet. However, insider selling and activist investor concerns over strategic direction highlight potential governance challenges ahead.

CRGO Debt to Equity History and Analysis as at Jul 2026
CRGO Debt to Equity History and Analysis as at Jul 2026

Niagen Bioscience (NAGE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products, with a market cap of $262.58 million.

Operations: The company's revenue is primarily derived from Consumer Products, which generated $98.58 million, followed by Ingredients at $29.07 million, and Analytical Reference Standards and Services contributing $2.69 million.

Market Cap: $262.58M

Niagen Bioscience, Inc., with a market cap of US$262.58 million, is making strides in the bioscience sector by expanding its NAD+ platform into drug development for rare genetic diseases. The recent FDA and EMA designations for its lead drug candidate NB4168 underscore regulatory support and potential growth in treating Ataxia Telangiectasia (A-T). Despite stable weekly volatility and no debt, Niagen's earnings growth has decelerated compared to its five-year average. Strategic partnerships enhance product distribution, while leadership changes aim to bolster research initiatives. The company trades significantly below estimated fair value but remains focused on advancing proprietary therapies globally.

NAGE Debt to Equity History and Analysis as at Jul 2026
NAGE Debt to Equity History and Analysis as at Jul 2026

VTEX (VTEX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: VTEX, along with its subsidiaries, offers a software-as-a-service digital commerce platform for enterprise brands and retailers, with a market cap of $693.88 million.

Operations: The company generates revenue from its Internet Software & Services segment, totaling $247.05 million.

Market Cap: $693.88M

VTEX, with a market cap of US$693.88 million, is enhancing its position in digital commerce by integrating AI across its platforms, aiming to automate operations and personalize customer experiences. Recent earnings show revenue growth to US$60.7 million for Q1 2026, with net income rising to US$4.06 million from the previous year. The company remains debt-free, with short-term assets significantly exceeding liabilities, indicating strong financial health. However, insider selling has been significant recently. VTEX's strategic focus on AI-driven solutions could create new revenue streams and improve operational efficiency in a competitive market landscape.

VTEX Revenue & Expenses Breakdown as at Jul 2026
VTEX Revenue & Expenses Breakdown as at Jul 2026

Next Steps

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.